Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
MD Hellmann, T-W Kim, CB Lee, B-C Goh, WH Miller, D-Y Oh, R Jamal, C-E Chee, LQM Chow, JF Gainor, J Desai, BJ Solomon, M Das Thakur, B Pitcher, P Foster, G Hernandez, MJ Wongchenko, E Cha, Y-J Bang, LL Siu Show all
Annals of Oncology | OXFORD UNIV PRESS | Published : 2019
BACKGROUND: Preclinical evidence suggests that MEK inhibition promotes accumulation and survival of intratumoral tumor-specific T cells and can synergize with immune checkpoint inhibition. We investigated the safety and clinical activity of combining a MEK inhibitor, cobimetinib, and a PD-L1 inhibitor, atezolizumab, in patients with solid tumors. PATIENTS AND METHODS: This phase I/Ib study treated PD-L1/PD-1-naive patients with solid tumors in a dose-escalation stage and then in multiple, indication-specific dose-expansion cohorts. In most patients, cobimetinib was dosed once daily orally for 21 days on, 7 days off. Atezolizumab was dosed at 800 mg intravenously every 2 weeks. The primary ob..View full abstract
This work was supported by F. Hoffmann-La Roche Ltd./Genentech, Inc., a member of the Roche Group (no grant number is applicable). All authors had access to the study data and confirm data accuracy and completeness.